{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-066738","form_type":"8-K/A","ticker":"GRDX","cik":"0001604191","company_name":"GridAI Technologies Corp.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.182733+00:00","generated_at":"2026-06-01T07:24:18.283671+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Entero Therapeutics files Q1 2024 pro forma statements post-ImmunogenX merger","bullets":["Amendment adds unaudited pro forma combined statement of operations for three months ended March 31, 2024.","Pro forma combined net loss applicable to common shareholders: $1,894,119.","Pro forma basic loss per share: $1.08; diluted loss per share: $1.08.","Merger with ImmunogenX closed March 13, 2024; Entero is accounting acquirer.","No changes to merger terms or business operations; filing purely supplemental."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-066738","json":"https://secwatch.observer/filing/0001104659-24-066738.json","markdown":"https://secwatch.observer/filing/0001104659-24-066738.md","text":"https://secwatch.observer/filing/0001104659-24-066738.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924066738/0001104659-24-066738-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924066738/tm2416013d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:24:18.283671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}